YAVNE, Israel, March 25, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, today announced the closing of its initial public offering of 5,750,000 ordinary shares at a price to the public of $14.00 per share. All of the shares of common stock in the offering were offered by MediWound and include 750,000 shares issued pursuant to the full exercise of the underwriters’ 30-day option to purchase up to 750,000 additional shares at the initial public offering price.
Help employers find you! Check out all the jobs and post your resume.
